Vycellix, Inc. is a privately-held biopharmaceutical company developing innovative products capable of optimizing human immune response against disease with a focus on cancers. The Company is advancing its proprietary pipeline of novel immunodudulators as therapeutics for cancers and infectious disease, as well as establishing these molecules as platform technology for the efficient, cost effective modulation of cell and gene therapies.

The NSU Cell Therapy Institute is a unique collaboration with leading medical research scientists from Nova Southeastern University and Sweden’s world-renowned Karolinska Institutet (KI) in Stockholm, Sweden. KI is globally recognized for its Nobel Assembly, which annually awards the Nobel Prize in Physiology or Medicine.The Institute is accelerating the advancement of next-generation approaches to precision medicine such as targeted immunotherapy and regenerative medicine with an initial… Show more The NSU Cell Therapy Institute is a unique collaboration with leading medical research scientists from Nova Southeastern University and Sweden’s world-renowned Karolinska Institutet (KI) in Stockholm, Sweden. KI is globally recognized for its Nobel Assembly, which annually awards the Nobel Prize in Physiology or Medicine.The Institute is accelerating the advancement of next-generation approaches to precision medicine such as targeted immunotherapy and regenerative medicine with an initial focus on treating cancers, heart disease and disorders causing blindness. Show less

From 2000 - 2007, Mr. Calder was responsible for all functions related to Investor Relations and Public Relations for the biopharmaceutical companies, Viragen, Inc. and Viragen International, Inc.